Actively Recruiting
Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer
Led by AstraZeneca · Updated on 2026-04-17
294
Participants Needed
60
Research Sites
235 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
GEMINI-Hepatobiliary study will assess the efficacy, safety and tolerability of novel immunomodulators alone and in combination with other anticancer drugs in participants with specified advanced solid tumors.
CONDITIONS
Official Title
Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older at the time of signing the informed consent form
- Signed and dated written informed consent form provided
- Confirmed locally advanced or metastatic solid tumor as specified in substudy by histopathology
- Adequate organ and bone marrow function
- At least 1 measurable lesion not previously treated with radiation according to RECIST 1.1
- Life expectancy of at least 12 weeks at screening
- Willing and able to provide an adequate tumor sample
You will not qualify if you...
- History of allogeneic organ transplantation
- Active or prior documented autoimmune or inflammatory disorders
- Uncontrolled intercurrent illness
- History of another primary malignancy, leptomeningeal carcinomatosis, or active primary immunodeficiency
- Active infection, brain metastases, or spinal cord compression
- Co-infection with hepatitis B virus (HBV) and hepatitis D virus (HDV)
- Previous treatment in this study
- For substudy 1, history of hepatic encephalopathy within 12 months prior to treatment allocation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 60 locations
1
Research Site
Birmingham, Alabama, United States, 35233
Actively Recruiting
2
Research Site
Costa Mesa, California, United States, 92627
Withdrawn
3
Research Site
Los Angeles, California, United States, 90089
Actively Recruiting
4
Research Site
Orange, California, United States, 92868
Actively Recruiting
5
Research Site
Miami Beach, Florida, United States, 33140
Withdrawn
6
Research Site
Dyer, Indiana, United States, 46311
Withdrawn
7
Research Site
Kansas City, Kansas, United States, 66103
Actively Recruiting
8
Research Site
New York, New York, United States, 10065
Actively Recruiting
9
Research Site
Dallas, Texas, United States, 75251
Withdrawn
10
Research Site
Fairfax, Virginia, United States, 22031
Withdrawn
11
Research Site
Beijing, China, 100050
Actively Recruiting
12
Research Site
Beijing, China, 100142
Actively Recruiting
13
Research Site
Beijing, China, 101100
Actively Recruiting
14
Research Site
Chengdu, China, 610000
Actively Recruiting
15
Research Site
Chengdu, China, 610041
Actively Recruiting
16
Research Site
Chongqing, China, 400030
Actively Recruiting
17
Research Site
Fuzhou, China, 350007
Actively Recruiting
18
Research Site
Guangzhou, China, 510060
Actively Recruiting
19
Research Site
Guangzhou, China, 510515
Actively Recruiting
20
Research Site
Harbin, China, 150081
Actively Recruiting
21
Research Site
Hefei, China, 230001
Withdrawn
22
Research Site
Hefei, China, 230022
Withdrawn
23
Research Site
Hefei, China, 230601
Withdrawn
24
Research Site
Nanchang, China, 330006
Withdrawn
25
Research Site
Nanning, China, 530021
Actively Recruiting
26
Research Site
Shandong, China
Withdrawn
27
Research Site
Shanghai, China, 200032
Actively Recruiting
28
Research Site
Xi'an, China, 710038
Withdrawn
29
Research Site
Zhengzhou, China, 450008
Withdrawn
30
Research Site
Hong Kong, Hong Kong, 999077
Actively Recruiting
31
Research Site
Shatin, Hong Kong, 00000
Actively Recruiting
32
Research Site
Florence, Italy, 50134
Actively Recruiting
33
Research Site
Milan, Italy, 20132
Actively Recruiting
34
Research Site
Naples, Italy, 80131
Actively Recruiting
35
Research Site
Rozzano, Italy, 20089
Actively Recruiting
36
Research Site
Chūōku, Japan, 104-0045
Actively Recruiting
37
Research Site
Kashiwa, Japan, 277-8577
Actively Recruiting
38
Research Site
Yokohama, Japan, 241-8515
Actively Recruiting
39
Research Site
Seongnam-si, South Korea, 463-712
Actively Recruiting
40
Research Site
Seoul, South Korea, 03080
Actively Recruiting
41
Research Site
Seoul, South Korea, 03722
Actively Recruiting
42
Research Site
Seoul, South Korea, 05505
Actively Recruiting
43
Research Site
Seoul, South Korea, 06351
Actively Recruiting
44
Research Site
Barcelona, Spain, 08036
Actively Recruiting
45
Research Site
Barcelona, Spain, 8035
Actively Recruiting
46
Research Site
Madrid, Spain, 28007
Actively Recruiting
47
Research Site
Madrid, Spain, 28040
Actively Recruiting
48
Research Site
Pamplona, Spain, 31008
Actively Recruiting
49
Research Site
Kaohsiung City, Taiwan, 80756
Actively Recruiting
50
Research Site
Kaohsiung City, Taiwan, 833
Actively Recruiting
51
Research Site
Liuying, Taiwan, 736
Actively Recruiting
52
Research Site
Taichung, Taiwan, 40705
Actively Recruiting
53
Research Site
Tainan, Taiwan, 70403
Actively Recruiting
54
Research Site
Taipei, Taiwan, 10002
Actively Recruiting
55
Research Site
Taipei, Taiwan, 11259
Actively Recruiting
56
Research Site
Taoyuan, Taiwan, 333
Actively Recruiting
57
Research Site
Cambridge, United Kingdom, CB2 0QQ
Actively Recruiting
58
Research Site
Edinburgh, United Kingdom, EH4 2XU
Withdrawn
59
Research Site
London, United Kingdom, NW3 2QG
Actively Recruiting
60
Research Site
Manchester, United Kingdom, M20 4BX
Actively Recruiting
Research Team
A
AstraZeneca Clinical Study Information Center
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
7
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here